STUDI PENGGUNAAN LOPINAVIR/RITONAVIR PADA PASIEN COVID-19 DERAJAT RINGAN-SEDANG DENGAN KOMORBID HIPERTENSI DAN DIABETES MELLITUS

Didik Hasmono; Agriawan Sudirman; Muhammad Nashrullah; Ruddy Hartono; Mohammad Subhan

doi:10.24252/kesehatan.v16i1.28711

Didik Hasmono Universitas Airlangga
(ID)
Agriawan Sudirman Faculty of pharmacy, Universitas Megarezky, Makassar
(ID)
Muhammad Nashrullah Pharmacy Student, Faculty of Pharmacy, Universitas Airlangga, Surabaya
(ID)
Ruddy Hartono Clinical Pharmacist in Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya
(ID)
Mohammad Subhan Pulmonologist in Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya
(ID)

DOI: https://doi.org/10.24252/kesehatan.v16i1.28711

Kata Kunci: Covid-19, Hypertention, Diabetes Mellitus, Lopinavir, Ritonavir

Abstrak

Lopinavir/Ritonavir diusulkan sebagai salah satu terapi untuk pasien Covid-19 berdasarkan kemampuan menurunkan viral load. Rumah Sakit Bhayangkara Surabaya merupakan salah satu rumah sakit dengan pasien Covid-19 yang cukup banyak di Surabaya. Penelitian ini bertujuan untuk mengetahui efektivitas, outcome, dan evaluasi efek samping Lopinavir/Ritonavir pada pasien Covid-19 ringan sampai sedang dengan komorbiditas hipertensi dan diabetes mellitus di RS Bhayangkara Surabaya. Penelitian ini merupakan penelitian observasional yang mengumpulkan data secara retrospektif di RS Bhayangkara Surabaya. Data pasien harus memenuhi syarat kriteria inklusi, yaitu pasien yang diobati dengan Lopinavir/Ritonavir untuk Covid-19 ringan sampai sedang dengan penyakit penyerta hipertensi dan diabetes mellitus. Data diperoleh 18 rekam medis pasien kemudian diolah secara deskriptif. Hasil penelitian menunjukkan 7 pasien (39%) mendapat terapi A dengan pengobatan 11 hari, 4 pasien mendapat terapi B (22%) dengan pengobatan 12 hari, 1 pasien (11%) mendapat terapi C dengan pengobatan 18 hari, dan 6 pasien (28%) menjalani terapi D dengan 14 hari pengobatan. Pasien mengalami efek gangguan gastrointestinal seperti mual (22%), dan diare (11%). Lopinavir/Ritonavir pada terapi A paling efektif jika dilihat dari lama pengobatan yaitu 11 hari. Terapi B, C, dan D dinilai efektif dilihat dari hasil RT-PCR yang menunjukkan hasil negatif yaitu 100%. Terapi D merupakan perbaikan rontgen dada yang paling efektif, yaitu 50%. Efek samping Lopinavir/Ritonavir adalah gangguan saluran cerna yaitu mual (22%), diare (11%), sedangkan hepatotoksisitas tidak ditemukan.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

Referensi

Bonanad, C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fácila, L., Ariza, A., Núñez, J., & Cordero, A. (2020). The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. Journal of the American Medical Directors Association, 21(7), 915–918. https://doi.org/10.1016/J.JAMDA.2020.05.045

Brayfield, A. (2014). Martindale: The Complete Drug Reference 38th Edition Volume A. Pharmaceutical Press.

Burhan, E., Dwi Susanto, A., Isbaniah, F., Aman Nasution, S., Ginanjar, E., Wicaksono Pitoyo, C., Susilo, A., Firdaus, I., Santoso, A., Arifa Juzar, D., Kamsul Arif, S., Lolong Wulung, N. G., Muchtar, F., Pulungan, A. B., Ambara Sjakti, H., Prawira, Y., Dwi Putri, N., Adityaningsih, D., Fahrial Syam, A., … Mayung Sambo, C. (2020). PEDOMAN TATALAKSANA COVID-19.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., … Wang, C. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine, 382(19), 1787–1799. https://doi.org/10.1056/NEJMOA2001282

CDC. (2020). People with Certain Medical Conditions | CDC. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., Zhao, Y., Wang, H., Liu, Y., Yin, Z., Zhang, R., Wang, R., Yang, M., Hui, C., … Li, F. (2020). Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. European Heart Journal, 41(22), 2058–2066. https://doi.org/10.1093/EURHEARTJ/EHAA433

Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020). Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences, 11(1). https://doi.org/10.1186/S13293-020-00304-9

Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., Palfreeman, A., Raw, J., Elmahi, E., Prudon, B., Green, C., Carley, S., Chadwick, D., Davies, M., Wise, M. P., Baillie, J. K., Chappell, L. C., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 396(10259), 1345–1352. https://doi.org/10.1016/S0140-6736(20)32013-4

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Instiaty, Sri Darmayani, I. G. A. A. P., Marzuki, J. E., Angelia, F., William, Siane, A., Sary, L. D., Yohanes, L., Widyastuti, R., Nova, R., Simorangkir, D. S., Lonah, Safitri, Y., Aliska, G., & Gayatri, A. (2020). Antiviral treatment of covid-19: A clinical pharmacology narrative review. Medical Journal of Indonesia, 29(3), 332–345. https://doi.org/10.13181/MJI.REV.204652

Leung, J. M., Yang, C. X., Tam, A., Shaipanich, T., Hackett, T. L., Singhera, G. K., Dorscheid, D. R., & Sin, D. D. (2020). ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. European Respiratory Journal, 55(5). https://doi.org/10.1183/13993003.00688-2020

Levy, C., Lassailly, G., Parmentier, E., Duburcq, T., Mathurin, P., & Poissy, J. (2020). Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. The American College of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000828

Lim, J., Jeon, S., Shin, H. Y., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K. W., Kang, Y. M., Lee, B., & Park, S. J. (2020). Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. Journal of Korean Medical Science, 35(6). https://doi.org/10.3346/JKMS.2020.35.E79

Palmieri, L., Palmer, K., Lo Noce, C., Meli, P., Giuliano, M., Floridia, M., Tamburo de Bella, M., Piccioli, A., Brusaferro, S., Onder, G., Andrianou, X., Barbariol, P., Bella, A., Bellino, S., Benelli, E., Bertinato, L., Boros, S., Brambilla, G., Calcagnini, G., … Zona, A. (2021). Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. Aging Clinical and Experimental Research, 33(1), 193–199. https://doi.org/10.1007/S40520-020-01764-0/TABLES/2

Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, | Concetta, Zoccoli, A., Liberato Berrino, |, Racagni, G., Rossi, F., & Capuano, A. (2020). Current pharmacological treatments for COVID-19: What’s next? British Pharmacological Society. https://doi.org/10.1111/bph.v177.21/issuetoc

Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91–98. https://doi.org/10.1016/j.jare.2020.03.005

Umakanthan, S., Sahu, P., Ranade, A. V., Bukelo, M. M., Rao, J. S., Abrahao-Machado, L. F., Dahal, S., Kumar, H., & Kv, D. (2020). Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgraduate Medical Journal, 96(1142), 753–758. https://doi.org/10.1136/postgradmedj-2020-138234

WHO. (2020). WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/

Zhou, P., Yang, X. Lou, Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. Di, Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., … Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/S41586-020-2012-7

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine, 382(8), 727–733. https://doi.org/10.1056/NEJMOA2001017